Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Prostate Cancer Nuclear Medicine Diagnostics Market Report 2024

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024 – By Type (Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)), By Test Type (Preliminary Tests, Confirmatory Tests), By End User (Hospitals, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024

Starting Price : $5000.00 | Pages : 175 | Published : July 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2024

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Prostate Cancer Nuclear Medicine Diagnostics Market Definition

Prostate cancer nuclear medicine diagnostics refers to the process of using radioactive substances to detect and evaluate prostate cancer. These diagnostics help in the detection, staging, and management of prostate cancer by providing detailed functional information about the disease's extent and characteristics. Prostate cancer nuclear medicine diagnostics involve the use of radioactive substances (radiopharmaceuticals) that are introduced into the body, typically through injection, and emit gamma rays or positrons.

The main types of prostate cancer nuclear medicine diagnostics are single photon emission computed tomography (spect), and photon emission computed tomography (pet). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed, three-dimensional images of the body's functional processes. The various test types include preliminary tests and confirmatory tests. These are used by various end-users such as hospitals, clinics, and others.

Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

The prostate cancer nuclear medicine diagnostics market covered in this report is segmented –

1) By Type : Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)

2) By Test Type: Preliminary Tests, Confirmatory Tests

3) By End User: Hospitals, Clinics, Other End Users

Global Prostate Cancer Nuclear Medicine Diagnostics Market Size 2023 to 2028: Graph

Prostate Cancer Nuclear Medicine Diagnostics Market Size 2024 And Growth Rate

The prostrate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.75 billion in 2023 to $0.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increased demand for pet scans, increased urbanization, rise in disposable income, rise in need for accurate cancer diagnosis, increased emphasis on early detection.

Prostate Cancer Nuclear Medicine Diagnostics Market Growth Forecast

The prostrate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.49 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to rising prevalence of prostate cancer, increasing demand for positron emission tomography, rising awareness about environmental sustainability, rising frequency of cancers, increasing digital transformation. Major trends in the forecast period include product innovation, technological advancements, advancements in nuclear medicine imaging, improved radiopharmaceuticals and imaging methods, innovative radiopharmaceuticals.

Prostate Cancer Nuclear Medicine Diagnostics Market Driver: Fueling Growth In Prostate Cancer Nuclear Medicine Diagnostics Market

The rise in the prevalence of prostate cancer is expected to propel the growth of the prostate cancer nuclear medicine diagnostics market going forward. Prostate cancer is a type of cancer that occurs in the prostate, a small walnut-shaped gland in males that produces seminal fluid, which nourishes and transports sperm. The rising prevalence of prostate cancer is due to the aging population, lifestyle changes, and genetic factors. Prostate cancer nuclear medicine diagnostics provide valuable insights that enable clinicians to deliver more precise, effective, and personalized care to patients with prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based health organization, there are about 2.99 million new cases of prostate cancer and 35,250 deaths from prostate cancer. Furthermore, in 2021, according to the National Cancer Institute, a US-based government agency, the rate of new cases of prostate cancer was 116.5 per 100,000 men per year. Therefore, the rise in the prevalence of prostate cancer drives the prostate cancer nuclear medicine diagnostics market.

Global Prostate Cancer Nuclear Medicine Diagnostics Market Major Players

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH

Global Prostate Cancer Nuclear Medicine Diagnostics Market Trend: Advancements In Prostate Cancer Nuclear Medicine Diagnostics With Innovations, Therapies, and Regulatory Clearance

Major companies operating in the prostate cancer nuclear medicine diagnostics market are developing innovative diagnostic imaging techniques and getting US Food and Drug Administration (FDA) approval. FDA clearance for diagnostics ensures that healthcare providers and patients can access safe and practical tests for diagnosing and managing various medical conditions. For instance, in March 2022, Novartis, a Switzerland-based pharmaceutical corporation, launched Pluvicto(lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) of a specific type known as prostate-specific membrane antigen–positive (PSMA-positive) that has spread to other areas of the body. Pluvicto combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle), providing a precision cancer treatment that targets prostate cancer cells expressing the prostate-specific membrane antigen (PSMA).

Prostate Cancer Nuclear Medicine Diagnostics Market Merger And Acquisition: Life Healthcare Group Expands Diagnostic Imaging Services Through Acquisition Of TheraMed Nuclear

In March 2023, Life Healthcare Group, a South Africa-based healthcare company, acquired TheraMed Nuclear for an undisclosed amount. With this acquisition, Life Healthcare enhances its diagnostic imaging services, particularly in detecting and treating diseases like organ dysfunction and cancer. TheraMed Nuclear is a South Africa-based company that offers prostate cancer nuclear medicine diagnostics.

Regional Insights For The Global Prostate Cancer Nuclear Medicine Diagnostics Market

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2023. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports from The Business Research Company that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prostate Cancer Nuclear Medicine Diagnostics Market Report Forecast and Analysis
Report AttributeDetails
Market Size Value In 2024 $0.86 billion
Revenue Forecast In 2033 $1.49 billion
Growth Rate CAGR of 14.8% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Type: Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)
2) By Test Type: Preliminary Tests, Confirmatory Tests
3) By End User: Hospitals, Clinics, Other End Users
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Additional countries that can be covered in the report for an additional fee: Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics

    3. Prostate Cancer Nuclear Medicine Diagnostics Market Trends And Strategies

    4. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On The Market

    4.2. Ukraine-Russia War Impact On The Market

    4.3. COVID-19 Impact On The Market

    5. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Growth

    5.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation

    6.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Single Photon Emission Computed Tomography (SPECT)

    Photon Emission Computed Tomography (PET)

    6.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Preliminary Tests

    Confirmatory Tests

    6.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospitals

    Clinics

    Other End Users

    7. Prostate Cancer Nuclear Medicine Diagnostics Market Regional And Country Analysis

    7.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market

    8.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Prostate Cancer Nuclear Medicine Diagnostics Market

    9.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    9.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Prostate Cancer Nuclear Medicine Diagnostics Market

    10.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Prostate Cancer Nuclear Medicine Diagnostics Market

    11.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    11.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market

    12.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market

    13.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market

    14.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    14.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market

    15.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    15.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Prostate Cancer Nuclear Medicine Diagnostics Market

    16.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Prostate Cancer Nuclear Medicine Diagnostics Market

    17.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Prostate Cancer Nuclear Medicine Diagnostics Market

    18.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.2. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.3. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Prostate Cancer Nuclear Medicine Diagnostics Market

    19.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.2. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.3. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Prostate Cancer Nuclear Medicine Diagnostics Market

    20.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.2. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.3. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market

    21.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    21.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Prostate Cancer Nuclear Medicine Diagnostics Market

    22.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Prostate Cancer Nuclear Medicine Diagnostics Market

    23.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    23.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Prostate Cancer Nuclear Medicine Diagnostics Market

    24.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    24.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Prostate Cancer Nuclear Medicine Diagnostics Market

    25.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    25.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Prostate Cancer Nuclear Medicine Diagnostics Market

    26.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    26.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market

    27.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market

    28.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    28.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Prostate Cancer Nuclear Medicine Diagnostics Market

    29.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview

    29.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape And Company Profiles

    30.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape

    30.2. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles

    30.2.1. Cardinal Health

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. General Electric

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Bayer AG

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Novartis AG

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Siemens Healthineers AG

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major And Innovative Companies

    31.1. GE Healthcare

    31.2. Lantheus

    31.3. CURIUM PHARMA

    31.4. Telix Pharmaceuticals Ltd.

    31.5. Eckert & Ziegler AG

    31.6. Point Biopharma Global Inc.

    31.7. Point Biopharma

    31.8. Alliance Medical Ltd.

    31.9. SHINE Medical Technologies LLC

    31.10. PETNET Solution

    31.11. NorthStar Medical Radioisotopes LLC

    31.12. Global Medical Solutions LLC

    31.13. Isotope Technologies Garching (ITG)

    31.14. Jubilant Pharma Limited

    31.15. Blue Earth Diagnostics Inc.

    32. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking

    33. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Prostate Cancer Nuclear Medicine Diagnostics Market

    35. Prostate Cancer Nuclear Medicine Diagnostics Market Future Outlook and Potential Analysis

    35.1 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Countries Offering Most New Opportunities

    35.2 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Segments Offering Most New Opportunities

    35.3 Prostate Cancer Nuclear Medicine Diagnostics Market In 2028 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Cardinal Health Financial Performance
  • Table 75: General Electric Financial Performance
  • Table 76: Bayer AG Financial Performance
  • Table 77: Novartis AG Financial Performance
  • Table 78: Siemens Healthineers AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Cardinal Health Financial Performance
  • Figure 75: General Electric Financial Performance
  • Figure 76: Bayer AG Financial Performance
  • Figure 77: Novartis AG Financial Performance
  • Figure 78: Siemens Healthineers AG Financial Performance

The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth

Read More

Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis

Read More

How Will The Nuclear Medicine Market Grow In 2022?

Read More

What Is The Pediatric Imaging Market Overview In 2022?

Read More

Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company

Read More

Cancer Diagnostics Global Market Report 2024 – By Products (Companion Diagnostics, Molecular Diagnostics), By Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), By Application (Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications), By End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Cervical Cancer Diagnostics Global Market Report 2024 – By Diagnostic Test (Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests), By Age Group (Below 21, Age between 21 to 29, Age between 30 to 65, Above 65), By End User (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Lung Cancer Drugs Global Market Report 2024 – By Drugs (Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs), By Disease Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By End User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Prostate Cancer Drugs Global Market Report 2024 – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), By End User (Hospitals, Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Thyroid Cancer Drugs Global Market Report 2024 – By Drug Type (Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types), By Type (Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types), By End Users (Hospitals, Oncology Clinics, Research Organizations, Other End-Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Automotive Smart Key Global Market Report 2024 – By Type (Passive Key Less Access, Remote Key Less Access), By Installation (OEM, After Market), By Application (Single Function, Multi-Function) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Veterinary Infectious Disease Diagnostics Global Market Report 2024 – By Infection Type (Viral Infections, Bacterial Infections, Parasitic Infections, Other Infections), By Animal Type (Companion Animal, Food-Producing animals), By Technology (Immunodiagnostics, Molecular Diagnostic, Other Technologies), By End User (Reference Laboratories, Veterinary Hospitals and Clinics, Point of Care, Research Institutes and Universities, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biomedical Textiles Global Market Report 2024 – By Product Type (Non Implantable, Implantable), By Fabric (Non-Woven Biomedical Textiles, Woven Biomedical Textiles, Knitted Biomedical Textiles), By Fiber Type (Non Biodegradable, Biodegradable), By Applications (Ophthalmology, Neurology, Cardiology, Dentistry, Orthopedics, General Surgery And Treatment, Other Applications), By End Users (Hospitals, Ambulatory Centers, Clinics, Community Healthcare, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Frequently Asked Questions

What is the definition of the Prostate Cancer Nuclear Medicine Diagnostics market?

Prostate cancer nuclear medicine diagnostics refers to the process of using radioactive substances to detect and evaluate prostate cancer. These diagnostics help in the detection, staging, and management of prostate cancer by providing detailed functional information about the disease's extent and characteristics. Prostate cancer nuclear medicine diagnostics involve the use of radioactive substances (radiopharmaceuticals) that are introduced into the body, typically through injection, and emit gamma rays or positrons. For further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here

How will the Prostate Cancer Nuclear Medicine Diagnostics market drivers and restraints affect the Prostate Cancer Nuclear Medicine Diagnostics market dynamics? What forces will shape the Prostate Cancer Nuclear Medicine Diagnostics industry going forward?

The Prostate Cancer Nuclear Medicine Diagnostics market major growth driver - The prostrate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.75 billion in 2023 to $0.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increased demand for pet scans, increased urbanization, rise in disposable income, rise in need for accurate cancer diagnosis, increased emphasis on early detection. The prostrate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.49 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to rising prevalence of prostate cancer, increasing demand for positron emission tomography, rising awareness about environmental sustainability, rising frequency of cancers, increasing digital transformation. Major trends in the forecast period include product innovation, technological advancements, advancements in nuclear medicine imaging, improved radiopharmaceuticals and imaging methods, innovative radiopharmaceuticals.. For further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here

What is the forecast market size or the forecast market value of the Prostate Cancer Nuclear Medicine Diagnostics market?

The prostrate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.75 billion in 2023 to $0.86 billion in 2024 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increased demand for pet scans, increased urbanization, rise in disposable income, rise in need for accurate cancer diagnosis, increased emphasis on early detection. The prostrate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.49 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to rising prevalence of prostate cancer, increasing demand for positron emission tomography, rising awareness about environmental sustainability, rising frequency of cancers, increasing digital transformation. Major trends in the forecast period include product innovation, technological advancements, advancements in nuclear medicine imaging, improved radiopharmaceuticals and imaging methods, innovative radiopharmaceuticals. For further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here

How is the Prostate Cancer Nuclear Medicine Diagnostics market segmented?

The Prostate Cancer Nuclear Medicine Diagnostics market is segmented
1) By Type : Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)
2) By Test Type: Preliminary Tests, Confirmatory Tests
3) By End User: Hospitals, Clinics, Other End UsersFor further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here

Which region has the largest share of the Prostate Cancer Nuclear Medicine Diagnostics market? What are the other regions covered in the report?

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2023. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. For further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here.

Who are the major players in the Prostate Cancer Nuclear Medicine Diagnostics market?

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG , Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC , PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC , Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd. , Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH For further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here.

What are the key trends in the Prostate Cancer Nuclear Medicine Diagnostics market?

Major trend in the Prostate Cancer Nuclear Medicine Diagnostics market - Advancements In Prostate Cancer Nuclear Medicine Diagnostics With Innovations, Therapies, and Regulatory Clearance. For further insights on the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here.

What are the major opportunities in the Prostate Cancer Nuclear Medicine Diagnostics market? What are the strategies for the Prostate Cancer Nuclear Medicine Diagnostics market?

For detailed insights on the major opportunities and strategies in the Prostate Cancer Nuclear Medicine Diagnostics market, request a sample here.

How does the Prostate Cancer Nuclear Medicine Diagnostics market relate to the overall economy and other similar markets?

For detailed insights on Prostate Cancer Nuclear Medicine Diagnostics market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Prostate Cancer Nuclear Medicine Diagnostics industry?

For detailed insights on the mergers and acquisitions in the Prostate Cancer Nuclear Medicine Diagnostics industry, request a sample here.

What are the key dynamics influencing the Prostate Cancer Nuclear Medicine Diagnostics market growth? SWOT analysis of the Prostate Cancer Nuclear Medicine Diagnostics market.

For detailed insights on the key dynamics influencing the Prostate Cancer Nuclear Medicine Diagnostics market growth and SWOT analysis of the Prostate Cancer Nuclear Medicine Diagnostics industry, request a sample here.